Financial Shenanigans

Financial Shenanigans — ConvaTec Group plc (CTEC)

1. The Forensic Verdict

The accounting picture at ConvaTec is Watch, with several FY2025 yellow flags worth underwriting — not a clean bill, not a thesis breaker. Five-year cash conversion is genuinely strong, governance is institutional, Deloitte's audit opinion is unqualified, and there is no restatement, regulatory action, short report, or auditor concern in evidence. The risk concentrates in three FY2025 patterns: trade receivables rose 25% against revenue growth of 6.6%; the company redefined its headline free-cash-flow metric in the same year that "growth capex" more than doubled to $121M; and accounts payable expanded 29% as days payable extended by roughly ten days. Each is individually defensible but they cluster, and they cluster in a year of CEO and CFO transition. The single test that would most change the grade is whether DSO normalizes back below 55 days in 1H 2026 without fresh receivable factoring.

13-shenanigan scorecard

2. Breeding Ground

The structural risk environment is investor-grade with one persistent yellow flag around incentive design. ConvaTec was IPO'd in October 2016 by Nordic Capital and Avista Capital Partners; the founder/PE block is now fully institutional, with no holder above 5.2% of voting rights. Deloitte LLP has audited the group and was reappointed at the 2025 AGM with no qualification or emphasis-of-matter language; tenure since the 2016 IPO is in line with FTSE 100 norms and well below mandatory rotation. The board chair (Dr John McAdam, ex-Rentokil chair) and audit committee are externally credible. The single live conditioning factor is that executive compensation is anchored on adjusted measures: 40% of annual bonus on adjusted operating profit, 25% on organic revenue growth, 15% on free-cash-flow-to-equity (the metric just redefined), and 25% of LTIP on adjusted profit before tax. CEO Karim Bitar died in service during 2025 and CFO Fiona Ryder was promoted into the role mid-year — a leadership transition typically sets the moment when accounting choices get re-examined. The fact that a non-cash impairment, a metric redefinition and a working-capital expansion all crystallise in the same transition year is the texture worth watching; none of it is improper, but it is not a coincidence either.

The breeding-ground reading amplifies rather than dampens the FY2025 working-capital and metric flags. With adjusted measures driving 4/5 of variable pay and a freshly minted CFO/CEO pairing, the temptation to define generously is structurally present. What disciplines it: an external chair and audit committee, a long-tenured Big Four auditor, and an investor base that has shown it will read the cash-flow statement.

3. Earnings Quality

Reported earnings tell a less flattering story than adjusted earnings, and the gap is almost entirely non-cash and largely defensible. The $228M operating-profit gap between reported ($316M) and adjusted ($544M) operating profit in FY2025 breaks down into $134M of acquired-intangible amortisation (of which $95M traces to the 2008 Bristol-Myers Squibb spin-out and amortises off entirely by mid-2026), a $72M non-cash InnovaMatrix impairment driven by the CMS payment cut effective 1 January 2026, and ~$22M of acquisition/divestiture, termination, and other items. Only $12M of the $228M was cash-impacting in 2025 — a positive disclosure-quality signal. The bigger structural issue is that adjusted diluted EPS of 17.6¢ is 2.05× reported diluted EPS of 8.6¢, the largest such gap in five years. That gap will mechanically narrow in 2026–2027 as the BMS-era intangibles run off, but the current quantum still warrants caution about what "EPS growth" means in this name.

Revenue quality. Receivables tell the most useful story in FY2025. From FY2017 through FY2024, ConvaTec's year-end DSO oscillated between 53 and 61 days. In FY2025 it spiked to 62.7 days — the highest reading in the dataset — while inventory days widened to 142. Management's explanation is reasonable: the InnovaMatrix run-off pulled forward a high-margin Q4, the buyback and growth-capex deployment put pressure on payments, and the inventory build reflects the eight new product launches the company is running through 2026. Reasonable, but not yet verified. The 18.5pp gap between receivables growth and revenue growth is the largest I have on record for this name, and it is the single most important figure to test in the 1H 2026 release.

Capitalisation pattern. Capex/depreciation has run at 0.55–0.69× over the last four years, comfortably below 1.0×. In a normal industrial that would suggest under-investment. Here it is mechanical: depreciation includes the BMS-era intangible amortisation that has nothing to do with current operating cash needs. Strip out acquired-intangible amortisation and FY25 capex of $135M sits ~50% above pure tangible depreciation of ~$90M — supporting the company's narrative that growth capex is genuinely lifting capacity, not making up for prior under-investment. The flag worth monitoring is the $198M jump in PP&E in FY2025 against only $135M of capex; the residual likely reflects new IFRS 16 right-of-use additions, which are routine, but the disclosure could be sharper.

4. Cash Flow Quality

ConvaTec's cash machine is genuinely strong over five years, but FY2025 leaned on payables. Three-year operating cash flow of $1,234M against three-year net income of $496M produces a CFO/NI ratio of 2.49×, healthy on the face of it but mostly explained by the very high acquired-intangible amortisation that depresses GAAP net income while leaving cash untouched. Five-year free-cash-flow conversion of 1.77× tells the same story. The cleaner read is FCF after acquisitions: $629M cumulative over 2023–2025, or ~$210M/year — a credible, if not spectacular, free-cash machine for a $2.4B med-tech franchise.

The stacked chart is the clearest single image of the FY2025 quality issue. Receivables drained $84M of cash, inventory drained another $67M, and payables released +$111M — the largest single payables tailwind in eight years and the offset that kept reported OCF growing 19% YoY. Net working-capital impact was a $40M outflow, in line with the company's APM disclosure, but the gross composition is what matters: the OCF print is propped up by a payables stretch that must repeat in FY2026 to hold the trajectory. DPO of 169 days at year-end is already 30+ days above ConvaTec's 2017–2018 levels and well above what is normal for branded med-tech. Either the working-capital cycle is being permanently re-set (plausible — industry-wide payables stretch is a 2020s feature), or this is a one-time release that will reverse.

No factoring, securitisation, or supplier-finance scheme is disclosed in the FY2025 MD&A, and the receivables note in the 2024 reporting did not flag a programme either. That is a clean test: if the FY2025 receivables build is real and unfinanced, then it is genuinely a timing issue that should resolve. If a future disclosure reveals factoring activity or non-recourse arrangements, the working-capital quality flag would escalate from yellow to red.

5. Metric Hygiene

The FY2025 metric story is the single most important forensic finding because it is where management has the most discretion and where compensation lives. Two changes happened in the same reporting cycle. First, the calculation of free cash flow to capital and free cash flow to equity was redefined to exclude growth capex — defined as cash spent to develop new products and create or increase capacity, as distinct from "operational capex" used to maintain existing operations. Comparative was restated for the growth-capex split (so FY24 FCF-to-equity moves from a worse number to $361M). Second, growth capex itself doubled from $59M (restated) to $121M in FY2025. The two effects combine: the metric that drives 15% of the bonus and that is loudly highlighted in the CEO/CFO narrative — "free cash flow to equity of $362M with conversion of 101%" — would have been meaningfully lower under the old definition. The CFO acknowledged this on the call: "Using our previous definition, free cash flow to equity was 61%." That is a 40 percentage point swing.

The honest read on the metric story is that the redefinition is defensible in substance and questionable in timing. Substance: separating maintenance from growth capex is something investors have asked for in adjacent franchises, the company restated the comparative, and the reconciliation to reported net cash from operations ($605M FY25 / $576M FY24) is published in full. Timing: the change appeared in the year growth capex doubled, in the new CFO's first reporting cycle, in a year of CEO transition, with the metric driving 15% of variable pay — and the headline "101% conversion" in the press release does not state that it is a redefined version of the historical metric. It is the kind of presentation choice that, repeated, would push the grade. Repeated only once, and with the prior-definition number disclosed on the call, it stays yellow.

6. What to Underwrite Next

The forensic risk here does not justify a thesis change but should adjust how an analyst reads the next two prints. ConvaTec is a structurally strong cash machine with a real, externally driven impairment, a defensible — if conveniently timed — metric redefinition, and one genuine FY2025 working-capital flag. The accounting risk is best treated as a position-sizing input rather than a valuation haircut: if the 1H 2026 release shows the working-capital build reverses, the grade is Clean. If receivables stay elevated and payables tighten, the grade rises to Elevated and the FCF-to-equity metric needs to be reconciled to a self-built, definition-stable version before any cash-flow multiple is applied.